Not Signed In -
Celecoxib |
Celebrex |
Clinical Trial: Celecoxib Treatment for Lung Cancer
This study is not yet open for patient recruitment.
|
Purpose
This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Non-Small-Cell Lung Carcinoma | Drug: Celecoxib | Phase I |
MedlinePlus related topics: Cancer; Lung Cancer
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Placebo Control, Crossover Assignment, Bio-availability Study
Official Title: Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer
Study start: October 2004; Expected completion: September 2009
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Pathologically confirmed and surgically resectable non small cell lung cancer and subjects must be ineligible for or refuse, neoadjuvant therapy
Location and Contact Information
California
VA Greater Los Angeles Healthcare System, Los Angeles, California, 90073, United States
Steven M. Dubinett, M.D., Principal Investigator
More Information
Record last reviewed: April 2005
Last Updated: April 14, 2005
Record first received: April 14, 2005
ClinicalTrials.gov Identifier: NCT00108186
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-05-03
Source: ClinicalTrials.gov
Cache Date: May 4, 2005
Resources
- Celebrex (Drug Digest)
- Celebrex Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
